NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive Appoints Vice President of Legal Affairs

SAN DIEGO, June 14 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Jason Hannon has been appointed to the newly created position of Vice President of Legal Affairs. Mr. Hannon will be responsible for all corporate legal matters as well as regulatory filings and Sarbanes Oxley compliance. He will also serve as the Secretary to the Board of Directors and be a member of the Executive Management Committee.

Prior to NuVasive, Mr. Hannon was employed at Heller Ehrman, LLP, a San Francisco, CA-based law firm. His responsibilities at the firm included the areas of corporate acquisitions, private and public financings, Sarbanes Oxley implementation and SEC and other regulatory filings. In this position he worked closely with NuVasive and was a significant contributor to the Company's initial public offering. Mr. Hannon received his law degree from Stanford University and completed his undergraduate degree at the University of California, Berkeley.

Alexis V. Lukianov, Chairman and Chief Executive Officer, said, "The addition of Jason Hannon adds a tremendous asset to our ability to address expanding legal matters as the Company continues to execute on its growth strategy. We believe Jason's exemplary legal background combined with his extensive knowledge of NuVasive will allow him to seamlessly integrate into his new role. Jason will focus exclusively on executing our corporate legal transactions and Jonathan Spangler, Vice President and Chief Patent Counsel, will continue to focus on intellectual property and related product development matters."

About NuVasive

We are a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. Our product portfolio is focused on applications in the over $2 billion U.S. spine fusion market. Our current principal product offering includes a minimally disruptive surgical platform that we call Maximum Access Surgery, or MAS(TM), as well as classic fusion implants.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of our current product offerings-NeuroVision(R), a proprietary software-driven nerve avoidance system, MaXcess(R), a unique split-blade design retraction system and specialized implants, like SpheRx(TM) and CoRoent(TM)-that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. Our classic fusion portfolio is comprised predominantly of proprietary saline packaged bone allografts and internal fixation products. NuVasive also has a robust R&D pipeline emphasizing both MAS and motion preservation products such as Total Disc Replacement (TDR).

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to, NuVasive's ability to successfully integrate its new Vice President of Legal Affairs into its management team, and other risks and uncertainties more fully described in NuVasive's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at . NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

     Contact:                           Investors:
     Kevin C. O'Boyle                   Stephanie Carrington/Nick Laudico
     EVP & Chief Financial Officer      The Ruth Group
     NuVasive, Inc.                     646-536-7017/7030

NuVasive, Inc.